5MRD

How KaloBios Pharmaceuticals Inc (KBIO) is Bouncing Back from a Brutal Day

KaloBios Pharmaceuticals Inc (KBIO) is staging an incredible comeback from Tuesday's beat-down

Nov 25, 2015 at 2:38 PM
facebook X logo linkedin


KaloBios Pharmaceuticals Inc (NASDAQ:KBIO) is the biggest gainer on the Nasdaq this afternoon, bouncing back from Tuesday's brutal 53.6% loss. Specifically, the biotech stock has surged nearly 44% to flirt with $26.60, after the company responded to a delisting notice from the Nasdaq -- triggered by its failure to file a quarterly report -- by saying it "intends to file ... as soon as practicable."

KBIO has been nothing short of incredible this month, since news broke of a huge investment from Turing Pharmaceuticals CEO Martin Shkreli. Relative to its close at $2.07 on Nov. 18 -- the session prior to that development -- the stock has gained 1,185%.

Meanwhile, short sellers have been hitting the eject button at a rapid-fire rate -- while those who haven't are getting killed. During the last two reporting periods, short interest on KaloBios Pharmaceuticals Inc (NASDAQ:KBIO) plummeted close to 35%. At present, 14.1% of the stock's float is still sold short, though it would take less than two sessions to repurchase those positions, at typical volumes.
 

The $25k Day Trading Barrier is Gone. It's Time to Put Your Capital to Work.

For years, the PDT rule put a major roadblock in front of active traders. The barrier is no longer standing in the way.

But having more freedom doesn't mean every trade is worth taking. 

With Dynamite Day Trading Signals, you'll receive up to 2 options trade alerts per week, each targeting 50%+ gains in a single session.

NO holding positions overnight.

NO waiting weeks for a trade to develop.

Just focused options trades designed to capitalize on opportunities as they emerge.

👉 Get Access to Dynamite Day Trading Signals

MR content page
 
 
 
 

Follow us on X, Follow us on Twitter